Research Use Only: This product is supplied for laboratory research and in-vitro studies. Not for human or veterinary administration.
Hover to zoom
Identity Verified: LC-MS
(0 Reviews)
Rad140 Capsules (15mg) 60 Count
- Nonsteroidal SARM: Benzonitrile-oxadiazole scaffold with AR binding Ki 7 nM (comparable to DHT 10 nM), first described 2011, tissue-selective levator ani vs. prostate activity, oral bioavailability 27-75%
- Clinical Development: Phase 1 ER+/HER2- breast cancer (MTD 100 mg/day, t½ 44.7 hours), active Phase 1/2 trial (NCT05573126, Ellipses Pharma EP0062), discontinued for sarcopenia indications
- Safety Warnings: Dose-limiting hepatotoxicity (AST 59.1%, ALT 45.5%), cholestatic liver injury case reports, cardiotoxicity (myocarditis/myopericarditis), HPG axis suppression, WADA prohibited S1.2, not approved for medical use
- Metabolic Synergy Research
- In-Vitro Receptor Profiling
- HPLC Verified (≥98% Purity)
$99.00In Stock
Ships same-day if ordered before 2PM EST
1
Encrypted Checkout
Global Express
Research Overview
Technical Specifications
| Characteristic | Value |
|---|---|
| CAS Number | 1182367-47-0 |
| Molecular Weight | 393.83 Da |
Mechanism of Action
RAD 140 demonstrates high AR affinity with Ki = 7 nM (superior to testosterone at 29 nM and comparable to DHT at 10 nM). Shows excellent selectivity over other steroid hormone receptors-nearest off target is progesterone receptor (IC₅₀ = 750 nM vs 0.2 nM for progesterone). Functions as tissue selective mixed agonist/partial AR agonist with demonstrated activity in muscle and bone tissue while lack
Research Applications
- Androgen receptor (AR) binding affinity and selectivity profiling
- Tissue-selective AR agonism and partial agonist mechanism research
- SARM structure-activity relationship (SAR) and drug design studies
- Steroid hormone receptor selectivity and off-target profiling
- Anabolic vs androgenic tissue response differentiation research
- Comparative AR ligand efficacy in hormone-sensitive cancer models